Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BIIB144 in Healthy Adult Participants
NCT07662148Phase 1Recruiting
- Sponsor
- Biogen
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB144 (6 cohorts), sponsored by Biogen. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Jul 2026; status: recruiting.
02
Drugs
BIIB144
Beyond the preview
Go deeper on NCT07662148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662148.